论文部分内容阅读
目的 :观察厄贝沙坦与黄芪注射液联合治疗对肾性蛋白尿的影响。方法 :将 80例慢性肾病患者分为A组 (对比组 )和B组 (治疗组 ) ,A组为常规治疗 :低盐、低蛋白饮食、控制感染、控制血压等 ;B组在常规治疗的基础上 ,给予厄贝沙坦与黄芪注射液治疗。观察治疗 1个月前后 2 4h尿量、2 4h尿蛋白定量、血肌酐、血尿素和血浆白蛋白的变化。结果 :B组治疗后 2 4h尿量明显增加 ,P <0 .0 1,有非常显著差异 ;2 4h尿蛋白减少 ,P <0 .0 5 ,有显著差异 ;血浆白蛋白增加 ,P <0 .0 5 ,有显著差异。结论 :厄贝沙坦与黄芪注射液联合治疗能明显减少尿蛋白
Objective: To observe the effect of irbesartan and astragalus injection on renal proteinuria. Methods: Eighty patients with chronic kidney disease were divided into group A (control group) and group B (treatment group). Group A was treated routinely with low salt and low protein diet, infection control and blood pressure control. In group B, Based on the given Irbesartan and Astragalus injection treatment. The changes of urine volume, 24 h urinary protein, serum creatinine, blood urea and plasma albumin were observed before and after treatment for 1 month. Results: The urine volume increased significantly at 24 hours after treatment in group B (P <0.01), and there was a significant difference between the two groups (P <0.01). The proteinuria in 24 hours decreased significantly (P <0.05), and the plasma albumin increased .0 5, there are significant differences. Conclusion: Irbesartan and Astragalus injection can significantly reduce the urine protein